An analysis of CREDENCE, EMPA-REG, the CANVAS Program, and DECLARE-TIMI 58 found SGLT2 inhibitor use reduced dialysis, transplantation, or death due to kidney disease by 33%.
Article from:Mdmag.com, SGLT2 Inhibitors Protect Against Kidney Failure in Diabetics